Pilot Study of 89-Zr Panitumumab in Pancreas Cancer


The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

Full Title of Study: “Pilot Study of 89Zr Panitumumab in Pancreas Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2022


  • Drug: 89Zr-panitumumab
    • Imaging Agent

Arms, Groups and Cohorts

  • Experimental: 89Zr-Panitumumab
    • Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.

Clinical Trial Outcome Measures

Primary Measures

  • Safety of 89Zr-panitumumab as a molecular imaging agent
    • Time Frame: 7 days
    • Safety is defined by the number of CTCAE v5 grade 2 or higher adverse events by Day 7 determined that are significant, definitely, probably or possibly related to 89Zr-panitumumab. Safety data will be summarized by grade, severity, and type.

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed diagnosis of pancreatic cancer. Exclusion Criteria:

  • Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. – History of infusion reactions to monoclonal antibody therapies. – Pregnant or breastfeeding. – Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. – Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. – Severe renal disease or anuria. – Known hypersensitivity to deferoxamine or any of its components.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Stanford University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Andrei Iagaru, Principal Investigator, Stanford Universiy
  • Overall Contact(s)
    • Alexander A Valencia, 650-498-5185, alxndr@stanford.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.